1. Scrip
  2. >>New Products

Gilead HIV Sales Getting Boost From Switches To TAF-Based Combos

 
• By Joseph Haas

Eighty percent of patients who’ve received Genvoya so far are switched over from older Gilead regimens, while 10% have switched from non-Gilead drugs. In terms of cumulative prescriptions, the Genvoya launch is outpacing the launch of predecessor drug Stribild to date.

The future of Gilead Sciences Inc.’s HIV business depends on switching patients over to its newer HIV single-tablet regimens where the older Viread is replaced with the prodrug tenofovir alafenamide (TAF), and not only did it report strong starts in the third quarter, it has new evidence in hand that should help it convert patients from the old to the new.

In an interview with Scrip, Gilead’s VP-HIV Medical Affairs David Piontkowsky noted that at the recent 2016 Glasgow HIV meeting...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

The Expanding MASH Market: How Rezdiffra, Wegovy Might Coexist

 
• By Joseph Haas

FDA approval of Novo Nordisk's Wegovy for MASH was almost as anticipated as approval of the first drug, Madrigal's Rezdiffra. Now, the MASH treatment paradigm should evolve.

Pipeline Watch: Eight Approvals And Five Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Sanofi’s Wayrilz Gets Out Of The Blocks With First US Approval For ITP

 
• By Alexandra Shimmings

The FDA go-ahead makes it the first for a BTK inhibitor in immune thrombocytopenia. Sanofi hopes it will mark the start of a number of indications for rilzabrutinib.

Pharma Claps Back At Gonorrhea With Pipeline Progress

 
• By Alexandra Shimmings

With no advances for decades, the STI could soon be facing two new antibiotic threats, while a third novel therapy has just entered the clinic.

More from Scrip

Executives On The Move: New CEO At Mitsubishi Tanabe Pharma

Recent moves in the industry include C-suite changes at Mitsubishi Tanabe Pharma and Oculis Holding, plus clock.bio gets a new chief business officer from BioNTech.

Liver Injury REMS Delays Agios’s Pyrukynd US FDA Approval In Thalassemia

 
• By Mandy Jackson

Approval in alpha- and beta-thalassemia by a Sept. 7 action date seemed assured, but an FDA review of proposed REMS regarding potential liver injury pushed it back to Dec. 7.

‘Attenuated’ Survival Benefit In Bemarituzumab Trial Delays Filing Plans

 
• By Alaric DeArment

Amgen and Zai Lab said the final analysis of the FORTITUDE-101 trial showed a decreased magnitude of OS benefit in first-line gastric cancer.